Table 3

Duration of statin use and the risk of gastric cancer in diabetic patients
univariable analysis
Variable (Statin duration) Case Control P-value+ OR (95% CI)+
0.5-1.0 38 71 < .0001 0.375 (0.216 – 0.651)
1.0-1.5 12 61 < .0001 0.138 (0.059 – 0.319)
1.5-2.0 13 41 < .0001 0.152 (0.058 – 0.400)
≥2.0 36 194 < .0001 0.132 (0.080 – 0.219)
multivariable analysis
Variable (Statin duration) Case Control P-value OR (95% CI)
0.5-1.0 38 71 0.0016+ 0.446 (0.252 – 0.790) +
1.0-1.5 12 61 < .0001+ 0.143 (0.061 – 0.338) +
1.5-2.0 13 41 < .0001+ 0.178 (0.067 – 0.474) +
≥2.0 36 194 < .0001+ 0.154 (0.091 – 0.260) +
Aspirin 184 347 < .0001 0.618 (0.454 – 0.843)
Other lipid lowering agents 154 221 < .0001 0.144 (0.053 – 0.392)

(reference category: Unexposed group).

Conditional logistic regression analysis was used.

+ ; Bonferroni’s correction was used to adjust inflation type I error due to multiple testing.

(reference category: Unexposed group).

Conditional multiple logistic regression analysis was used.

+ ; Multiple conditional logistic regression with Bonferroni’s correction.

*Abbreviations: OR odds ratio.

Lee et al.

Lee et al. BMC Cancer 2012 12:596   doi:10.1186/1471-2407-12-596

Open Data